Oncotelic Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Oncotelic Therapeutics, Inc. (OTLC) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 70.55 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2024-04-12
- Oncotelic Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-06-30 was 13.80M shares.
- Oncotelic Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2020-06-30 was 6.58M shares.
- Oncotelic Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 70.55M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2022-12-31 | 70.55M shares 10-K · filed 2024-04-12 | |||
| 2022-09-30 | 35.10M shares 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 13.80M shares 10-Q · filed 2022-08-22 | 13.51M shares 10-Q · filed 2022-08-22 | ||
| 2020-06-30 | 6.58M shares 10-Q · filed 2021-08-20 |